कवर छवि

Bortezomib in Anti-Cancer Activity: A Potential Drug

<p>26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppressio...

पूर्ण विवरण

में बचाया:

ग्रंथसूची विवरण
मुख्य लेखकों:	Rajagopal Appavu (लेखक), Deepa Mohan (लेखक)
स्वरूप:	पुस्तक
प्रकाशित:	Global Journal of Cancer Therapy - Peertechz Publications, 2016-03-08.
विषय:	Mini Review
ऑनलाइन पहुंच:	Connect to this object online.
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन

Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
द्वारा: Britta Stadelmann, और अन्य
प्रकाशित: (2014)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
द्वारा: Pan Zhou, और अन्य
प्रकाशित: (2022)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
द्वारा: Hua Wang, और अन्य
प्रकाशित: (2018)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
द्वारा: Gül Kozalak, और अन्य
प्रकाशित: (2023)

Development and characterization of liposomal formulation of bortezomib
द्वारा: Anil K. Deshantri, और अन्य
प्रकाशित: (2019)

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
द्वारा: Syed M. Hasan MD, और अन्य
प्रकाशित: (2018)

The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells
द्वारा: Angéla Takács, और अन्य
प्रकाशित: (2021)

Successful treatment of mucous membrane pemphigoid with bortezomib
द्वारा: Lina Saeed, BS, और अन्य
प्रकाशित: (2018)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
द्वारा: Joseph Han, और अन्य
प्रकाशित: (2023)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
द्वारा: Pawel Robak, और अन्य
प्रकाशित: (2019)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
द्वारा: Vallumsetla N, और अन्य
प्रकाशित: (2015)

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib
द्वारा: Saeideh Allahyari, और अन्य
प्रकाशित: (2020)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
द्वारा: Mitsutoshi Satoh, और अन्य
प्रकाशित: (2011)

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects
द्वारा: Junpeng Nie, और अन्य
प्रकाशित: (2017)

Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
द्वारा: Emre Güven, और अन्य
प्रकाशित: (2024)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
द्वारा: Chen W, और अन्य
प्रकाशित: (2016)

Guillain-Barré syndrome of a patient under bortezomib treatment
द्वारा: María Mar Herráez-Albendea, और अन्य
प्रकाशित: (2020)

Catechol Containing Polyelectrolyte Complex Nanoparticles as Local Drug Delivery System for Bortezomib at Bone Substitute Materials
द्वारा: David Vehlow, और अन्य
प्रकाशित: (2020)

Skin lesions caused by bortezomib targeted therapy of multiple myeloma
द्वारा: Michał Sobjanek, और अन्य
प्रकाशित: (2016)

Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats
द्वारा: Shota Yamamoto, और अन्य
प्रकाशित: (2015)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
द्वारा: Chi Zhang, और अन्य
प्रकाशित: (2023)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
द्वारा: Paweł Robak, और अन्य
प्रकाशित: (2020)

Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis.
द्वारा: Parveen Kaur, और अन्य
प्रकाशित: (2020)

Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination
द्वारा: Lucile Hoch, और अन्य
प्रकाशित: (2022)

The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at physiological concentrations
द्वारा: Tran Tran Thi Van, और अन्य
प्रकाशित: (2024)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
द्वारा: Xiang Zhou, और अन्य
प्रकाशित: (2023)

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
द्वारा: Marcelle G. Meseeha, और अन्य
प्रकाशित: (2015)

Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells
द्वारा: Zar Chi Soe, और अन्य
प्रकाशित: (2019)

Supramolecular Caffeic Acid and Bortezomib Nanomedicine: Prodrug Inducing Reactive Oxygen Species and Inhibiting Cancer Cell Survival
द्वारा: Ludwig Erik Aguilar, और अन्य
प्रकाशित: (2020)

Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
द्वारा: Amany R Keruakous, और अन्य
प्रकाशित: (2021)

Gabapentin Inhibits Bortezomib-Induced Mechanical Allodynia Through Supraspinal Action in Mice
द्वारा: Ryo Kitamura, और अन्य
प्रकाशित: (2014)

Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion
द्वारा: Andrew R. Snavely, और अन्य
प्रकाशित: (2022)

Successful treatment of gamma 1 heavy chain deposition disease with bortezomib and dexamethasone
द्वारा: Masanori Sudo, और अन्य
प्रकाशित: (2019)

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone
द्वारा: Noman Ahmed Jang Khan MD, और अन्य
प्रकाशित: (2021)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
द्वारा: Shang-Yi Huang, और अन्य
प्रकाशित: (2019)

ID221 Bortezomib for the treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis
द्वारा: Vania dos Santos Nunes Nogueira, और अन्य
प्रकाशित: (2024)

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis
द्वारा: Sheng-Min Hsu, और अन्य
प्रकाशित: (2015)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
द्वारा: Tibullo eDaniele, और अन्य
प्रकाशित: (2015)

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma
द्वारा: Vidya Ramakrishnan, और अन्य
प्रकाशित: (2019)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
द्वारा: Jatin J Shah, और अन्य
प्रकाशित: (2009)